Navigation Links
Sunesis Reports Financial Results for the Second Quarter 2009
Date:7/29/2009

t over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

About Ovarian Cancer

In the United States, ovarian cancer remains the leading cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. According to the American Cancer Society, in 2008 there were an estimated 21,650 new cases and more than 15,000 deaths from ovarian cancer in the U.S. alone. Following frontline treatment, recurrence rates among ovarian cancer patients are high. Treatment options remain limited following relapse, and overall long-term survival has not changed significantly over the past 40 years, with five-year survival rates at less than 30 percent.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc. All other trademarks appearing in this release are the property of their respective owners.

This press rele
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Grace Century, a private ... projects, announces the addition of Dr. Yousef “Josh” ... advisory team. Dr. Siddiqui will provide further healthcare expertise ... graduate of University College Medical School in ... medicine in 2001. With further certification as a General ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced next steps for its Oral Amphotericin B ... its in vitro work involving samples ... now plans to complete pre clinical studies and ... Phase 1A clinical trial, utilizing approximately $700,000 of ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... (Medication Dispensing Systems, Packaging and Labeling Systems, Table-top ... Automation) - Global Forecasts & Trends to 2019” ... and opportunities in North America, Europe, Asia-Pacific, and ... 101 market tables and 30 figures spread through ...
(Date:10/20/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... to $5.8 million and provides a good start to Q4.  The ... America and one in the Middle East ... record levels," said Peter Bruijns , President & CEO. "Total ... Q3 than they have been for any complete year since the ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... to $33.2 Million, ... $12.8 Million, -- The Company Provides ... NEW YORK and HAIKOU, Hainan, China, March 31,/Xinhua-PRNewswire-FirstCall/ -- ... which develops, manufactures, and,markets generic and branded bio-pharmaceutical products ...
... on Lead Compounds That Directly and Specifically Activate ... ... Massachusetts, March 31 Mercury Therapeutics,Inc. (MTI), a company that discovers ... filed for patent protection on,three lead compounds that directly and specifically ...
... Vaccine Technology and ... Bird Flu Clinical Program, Webcast/teleconference Call Set ... March 31 Carrington,Laboratories, Inc. (OTC Bulletin Board: CARN) today reported ... ($0.90) per basic and,diluted share, for the year ended December 31, ...
Cached Biology Technology:China Pharma Holdings, Inc. Announces Record 2007 Year End Results 2China Pharma Holdings, Inc. Announces Record 2007 Year End Results 3China Pharma Holdings, Inc. Announces Record 2007 Year End Results 4China Pharma Holdings, Inc. Announces Record 2007 Year End Results 5China Pharma Holdings, Inc. Announces Record 2007 Year End Results 6China Pharma Holdings, Inc. Announces Record 2007 Year End Results 7China Pharma Holdings, Inc. Announces Record 2007 Year End Results 8China Pharma Holdings, Inc. Announces Record 2007 Year End Results 9China Pharma Holdings, Inc. Announces Record 2007 Year End Results 10China Pharma Holdings, Inc. Announces Record 2007 Year End Results 11Mercury Therapeutics Patents Filed 2Mercury Therapeutics Patents Filed 3Carrington Reports 2007 Financial Results 2Carrington Reports 2007 Financial Results 3Carrington Reports 2007 Financial Results 4Carrington Reports 2007 Financial Results 5Carrington Reports 2007 Financial Results 6Carrington Reports 2007 Financial Results 7
(Date:10/16/2014)... be cultivated efficiently, they are anything but sustainable: ... monoculture cultivation is becoming increasingly evident. Despite their ... and are regarded as the sole possibility of ... wrongfully, finds Bernhard Schmid, an ecology professor at ... form of agriculture and forestry. After all, a ...
(Date:10/15/2014)... PORT WASHINGTON, N.Y. , Oct. 15, 2014 ... in technology solutions for home and community-based care, ... the benefits of implementing Sandata,s Santrax® Electronic Visit ... Quality Care Services is a home health company ... Texas . ...
(Date:10/15/2014)... spreading rapidly and to an unexpected extent. The outbreak ... and the virus shows a new disease dynamic in ... this reason, the German National Academy of Sciences Leopoldina, ... and the Union of the German Academies of Sciences ... epidemic today. , In the statement the academies call ...
Breaking Biology News(10 mins):Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Sandata Announces Case Study with Quality Care Services, Inc. 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... 2012 Aware, Inc. (NASDAQ: AWRE ), a leading ... financial results for its first quarter ended March 31, 2012.  ... million, a decrease of 10% compared to $6.4 million in the ... 2012 was $1.1 million, or $0.05 per diluted share. These results ...
... Huntington disease (HD) is an inherited neurodegenerative disorder ... the Huntingtin gene, a CAG repeat occurs too many ... or 50s, but studies have shown that significant brain ... diagnosis. As a result, the field has sought a ...
... of Plant Biologists (ASPB) is pleased to announce the recipients ... and service. Charles Reid Barnes Life Membership ... University of Florida, Gainesville , Established in 1925, the ... honoring lifelong service in plant biology. Hanson, this year,s honoree, ...
Cached Biology News:Aware, Inc. Reports First Quarter 2012 Financial Results 2Aware, Inc. Reports First Quarter 2012 Financial Results 3Aware, Inc. Reports First Quarter 2012 Financial Results 4Aware, Inc. Reports First Quarter 2012 Financial Results 5Striatal brain volume predicts Huntington disease onset 2ASPB names 2012 award recipients 2ASPB names 2012 award recipients 3ASPB names 2012 award recipients 4ASPB names 2012 award recipients 5
...
BD Falcon microtest assay plate. 1536 well 12l, black, flat-bottom PS. Polystyrene, nonsterile, no lid. (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... Black wall plates have low ... reduced crosstalk,• Not treated (or medium ... nature and binds biomolecules through passive ... the immobilization of large molecules, such ...
... 1575 immunowash microplate washer, 100-240 V, is ... flat-, U-, or V-bottom wells. This washer ... positions to an accuracy of 0.1 mm ... washing. It can store up to 75 ...
Biology Products: